Scarica l'app Stockscreener
0.904
0.46%
-0.0042
Pre-mercato:
.89
-0.014
-1.55%
Oncolytics Biotech Inc Borsa (ONCY) Ultime notizie
Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer - Moomoo
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress - Investing.com UK
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress By Investing.com - Investing.com South Africa
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech shares climb ahead of planned FDA meeting on REO 033 trial (ONCY) - MSN
Oncolytics advances colorectal cancer trial, plans FDA meeting By Investing.com - Investing.com Australia
Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY) - Yahoo Finance
Oncolytics (ONCY) Updates on REO 033 Clinical Study Progress - GuruFocus
Oncolytics Biotech stock jumps on FDA meeting plans for trial - Investing.com
Oncolytics advances colorectal cancer trial, plans FDA meeting - Investing.com
Cancer trial using pelareorep seeks FDA input on path to possible approval - Stock Titan
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech Inc (ONCY) Institutional Confidence - TradingKey
Oncolytics Biotech (NASDAQ:ONCY) Shares Up 16.1%What's Next? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Oncolytics Biotech Inc. Replaces Ernst & Young with Baker Tilly as Independent Auditor in 2026 Corporate Restructuring – Minichart - Minichart
Oncolytics Biotech (ONCY) replaces Ernst & Young with Baker Tilly as 2026 auditor - Stock Titan
NMAD Stock Price and Chart — NASDAQ:NMAD - TradingView
Oncolytics Biotech Inc. Actuals & Estimates (NASDAQ:ONCY) - TradingView
ONCY Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Oncolytics Biotech Inc. – NASDAQ:ONCY - TradingView
Price to sales forward of Oncolytics Biotech Inc. – NASDAQ:ONCY - TradingView
Oncolytics Biotech Inc (ONCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oncolytics Biotech Inc (ONCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oncolytics Biotech | 8-K: Current report - Moomoo
Oncolytics Biotech StockWeekly review and sector backdrop - AD HOC NEWS
Oncolytics Biotech | F-10POS: Others - Moomoo
Oncolytics Biotech Inc (ONCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oncolytics Biotech Inc (ONCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oncolytics Biotech Inc (ONCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oncolytics Biotech® to Host Conference Call to Discuss First Qua - GuruFocus
Oncolytics Biotech Inc (ONCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oncolytics Biotech Secures New Pelareorep Manufacturing Patent - The Globe and Mail
Oncolytics (ONCY) Secures New Patent for Pelareorep Manufacturin - GuruFocus
ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics - Yahoo Finance
Oncolytics receives U.S. patent for pelareorep manufacturing By Investing.com - Investing.com South Africa
Oncolytics Gets US Patent for Pelareorep Manufacturing Process - marketscreener.com
Oncolytics receives U.S. patent for pelareorep manufacturing - Investing.com
Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process - TradingView
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 - The Manila Times
New pelareorep patent extends Oncolytics Biotech (Nasdaq: ONCY) IP to 2044 - Stock Titan
Oncolytics Builds a 20-Year Patent Fortress for Its Cancer Immunotherapy - BriefGlance
Oncolytics Biotech® to Participate in a Panel Presentation at Ca - GuruFocus
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
JonesTrading Maintains Oncolytics Biotech(ONCY.US) With Hold Rating - Moomoo
Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights - ACCESS Newswire
ONCY: Promising GI cancer data and new patent strategies position pelareorep for major milestones - TradingView
0.27%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):